A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017

NCT06980207 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Hallucinations and Delusions Associated With Parkinson Disease Psychosis
Negative Symptoms of Schizophrenia

Interventions

DRUG: LY03017
DRUG: LY03017-Placebo

Sponsor

Luye Pharma Group Ltd.